US FDA cites Apotex's Bangalore drug facility for fraudulent data

Tags: News
An Indian subsidiary of Canadian drug company Apotex Inc manipulated laboratory data, retesting samples until the results were acceptable, according to a warning letter posted by the U.S. Food and Drug Administration on its website on Tuesday.

The letter, dated June 16, referenced an FDA inspection that took place in January at the company's facility in Bangalore, where inspectors found significant deviations from good manufacturing practices.

The inspection found that the company, which makes pharmaceutical ingredients, routinely completed sample analyses and recorded the data only if the results were acceptable.

"If the results obtained were atypical, a fresh sample was to be prepared and analyzed," the FDA said in its letter. "The original sample testing was not recorded."

In April, the FDA banned imports from the facility, saying it did not comply with quality standards. The move followed similar bans on certain products from Indian drugmakers Ranbaxy Laboratories Ltd, Wockhardt Ltd and Sun Pharmaceutical Industries Ltd.

The FDA said a response by privately held Apotex in February to the agency's inspection report "lacks sufficient corrective actions" and that the issues raised during the inspection "demonstrate a general lack of reliability and accuracy of data generated by your firm's laboratory."

The agency said the company's failure to create and maintain accurate documentation "is a repeat observation reported to your facility during the 2006 and 2010 inspections."

The FDA said that until the company corrects all the deviations, it may withhold approval of any new product applications.

Apotex officials were not immediately available.

Post new comment

E-mail ID will not be published
CAPTCHA
This question is for testing whether you are a human visitor and to prevent automated spam submissions.

EDITORIAL OF THE DAY

  • FDI in insurance must be allowed with a rider to increase penetration

    The Union cabinet has cleared the proposal to raise foreign direct investment (FDI) in the insurance sector through the FIPB route from the current 26

FC NEWSLETTER

Stay informed on our latest news!

INTERVIEWS

GV Nageswara Rao

MD & CEO, IDBI Federal Life

Timothy Moe

Goldman Sachs

Chander Mohan Sethi

CMD, Reckitt Benckiser India

COLUMNIST

Varun Dutt

Which is safer? Flying or driving?

The recent tragedies involving the Taiwan’s TransAsia Airways flight, and ...

Parvez Imam

Revisiting history can do us all good

We often think that we understand history. We read it ...

Bubbles Sabharwal

Your happiness doesn’t depend on your needs

They are two different words (and even worlds) altogether: having ...

INTERVIEWS

William D. Green

Chairman & CEO, Accenture